Emerging trends of liquid crystalline nanoparticles drug delivery for pulmonary disorders

Singh, VP; Mehta, M; Satija, S; Sharma, DS; Sharma, PK

Emerging trends of liquid crystalline nanoparticles drug delivery for pulmonary disorders

Singh, VP Mehta, M Satija, S

Sharma, DS Sharma, PK

Permalink

Publication Type:: Journal Article
Citation:: European Journal of Molecular and Clinical Medicine, 2020, 7, (7), pp. 2558-2564
Issue Date:: 2020-09-01

Closed Access

	Filename	Description	Size
	EJMCM_Volume 7_Issue 7_Pages 2558-2564.pdf	Published version	255.7 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Singh, VP
dc.contributor.author	Mehta, M
dc.contributor.author	Satija, S https://orcid.org/0000-0003-4702-6534
dc.contributor.author	Sharma, DS
dc.contributor.author	Sharma, PK
dc.date.accessioned	2021-05-14T03:28:21Z
dc.date.available	2021-05-14T03:28:21Z
dc.date.issued	2020-09-01
dc.identifier.citation	European Journal of Molecular and Clinical Medicine, 2020, 7, (7), pp. 2558-2564
dc.identifier.issn	2515-8260
dc.identifier.uri	http://hdl.handle.net/10453/148901
dc.description.abstract	© 2020 Ubiquity Press. All rights reserved. In this era of nanotechnology lyotropic liquid crystalline nanoparticles (cubosomes) are relatively less explored lipid-based nanocarriers that can be formulated selectively and specificity for almost all administration routes. The natural compounds are proved to be significantly curative in pulmonary diseases due to reported anti-oxidant, anti-inflammatory and immunomodulatory activities. The natural products have limited bioavailability due to either hydrophilic or low water solubility. These limitations can be overcome by using a novel nanotechnology such as cubosomes or liquid crystalline nanoparticles (LCNs). LCNs can easily encapsulate both hydrophilic and hydrophobic compounds because of the amphiphilic nature of lipid monoolein (MO). LCN can be used to co-deliver synthetic and natural compounds irrespective of their solubility due to multi-compartment structure. We can use LCNs to formulate drugs of synthetic origin with natural one to overcome multidrug resistance (MDR).
dc.language	en
dc.relation.ispartof	European Journal of Molecular and Clinical Medicine
dc.rights	info:eu-repo/semantics/closedAccess
dc.title	Emerging trends of liquid crystalline nanoparticles drug delivery for pulmonary disorders
dc.type	Journal Article
utslib.citation.volume	7
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
utslib.copyright.status	closed_access	*
dc.date.updated	2021-05-14T03:28:20Z
pubs.issue	7
pubs.publication-status	Published
pubs.volume	7
utslib.citation.issue	7

Abstract:

© 2020 Ubiquity Press. All rights reserved. In this era of nanotechnology lyotropic liquid crystalline nanoparticles (cubosomes) are relatively less explored lipid-based nanocarriers that can be formulated selectively and specificity for almost all administration routes. The natural compounds are proved to be significantly curative in pulmonary diseases due to reported anti-oxidant, anti-inflammatory and immunomodulatory activities. The natural products have limited bioavailability due to either hydrophilic or low water solubility. These limitations can be overcome by using a novel nanotechnology such as cubosomes or liquid crystalline nanoparticles (LCNs). LCNs can easily encapsulate both hydrophilic and hydrophobic compounds because of the amphiphilic nature of lipid monoolein (MO). LCN can be used to co-deliver synthetic and natural compounds irrespective of their solubility due to multi-compartment structure. We can use LCNs to formulate drugs of synthetic origin with natural one to overcome multidrug resistance (MDR).

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/148901